Talaris Therapeutics, Inc. (TALS) Financials

TALS Assets vs Liabilities

DateAssetsLiabilities
June 30, 2023 159.1 million 10.7 million
March 31, 2023 172.6 million 10.9 million
Dec. 31, 2022 193.7 million 13.7 million
Sept. 30, 2022 206.5 million 11.7 million

TALS Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2023 -14.9 million 1.2 million
March 31, 2023 -17.2 million 3.7 million
Dec. 31, 2022 -14.1 million 3.1 million
Sept. 30, 2022 -13.8 million 3.0 million

TALS Net Income

No data available :(

TALS Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2023 152.3 million - 1.0 million
March 31, 2023 165.8 million - 1.3 million
Dec. 31, 2022 181.3 million - 2.9 million
Sept. 30, 2022 193.9 million - 3.1 million

TALS Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2023 42.2 million
March 31, 2023 41.8 million
Dec. 31, 2022 41.2 million
Sept. 30, 2022 41.4 million

TALS Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2023 221000 4.1 million 6.0 million -
March 31, 2023 320000 13.4 million 6.2 million -
Dec. 31, 2022 269000 14.6 million 5.2 million -
Sept. 30, 2022 341000 15.0 million 4.8 million -

TALS Cost of Revenue

No data available :(

TALS

Price: $2.72

52 week price:
0.89
9.47

Earnings Per Share: -0.34 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.8 million

Market Capitalization: 125.7 million

Links: